The recommendation, published in The BMJ, states that multiple clinical trials of more than 6,000 people have shown that hydroxychloroquine has no meaningful effect on death or hospital admissions in people with no prior exposure to COVID-19, according to The Hill.
The trials also showed a “moderate certainty” that hydroxychloroquine increases the risk of adverse effects.
“The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19,” the WHO said.
Hydroxychloroquine is FDA approved to treat malaria, lupus and rheumatoid arthritis.
More articles on pharmacy:
How J&J’s COVID-19 vaccine compares to Moderna’s, Pfizer’s
Merck to manufacture J&J’s COVID-19 vaccine
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
